Table 1.

Prodrugs in clinic and clinical development.

Drug name	Originator/developer	Phase	Disease	Viral Target Mechanism of action		Ref
Sofosbuvir (Sovaldi, [24])	Pharmasset/Gilead Sciences	Approved 2013	HCV	NS5B RNA-dependent RNA polymerase inhibition		62
Tenofovir alafenamide(TAF, [25])	Gilead Sciences	Approved 2016Approved 2015	HBVHIV	HBV reverse transcriptase inhibitionHIV reverse transcriptase inhibition		63
INX‐08189 [33]	Inhibitex/BMS	Discontinued	HCV	NS5B RNA-dependent RNA polymerase inhibition		175
Stampidine [34]	Paradigm Pharmaceuticals, Parker Hughes Institute	I	HIV	RNA-directed DNA polymerase inhibition		213
MK‐3682 [35]	Merck	Discontinued	HCV	NS5B RNA-dependent RNA polymerase inhibition		223
GS‐6620 [36]	Gilead Sciences	I	HCV	NS5B RNA-dependent RNA polymerase inhibition		231
GS‐5734 [37]	Gilead Sciences	II	Ebola V	Viral RNA-dependent RNA polymerase inhibition		235